Semaglutide · research summary

Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.

JACC. Advances · 2026. Summary drawn from the study's abstract. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Observational cohort study
“We conducted an observational cohort study applying the SELECT trial's inclusion and exclusion criteria to patients with first-time MI recorded between 2010 and 2021 in the Western Denmark Heart Registry.”

Subjects

First-time myocardial infarction patients without diabetes meeting SELECT-eligibility criteria with BMI ≥27 kg/m2
“Five-year incidence of second MI, MACE, and all-cause death was estimated for SELECT-eligible patients with a body mass index (BMI) ≥27 kg/m2.”

Sample size

10,768 SELECT-eligible patients out of 21,777 first-time MI patients without diabetes
“In 21,777 first-time MI patients without diabetes, 10,768 patients were SELECT-eligible with BMI ≥27 kg/m2.”

Duration

Five-year incidence estimation for patients recorded between 2010 and 2021
“Five-year incidence of second MI, MACE, and all-cause death was estimated for SELECT-eligible patients with a body mass index (BMI) ≥27 kg/m2.”

Reported findings

Five-year incidence of MACE was 10.7% in SELECT-eligible MI patients
“Five-year incidence of second MI (n = 544), MACE (n = 975), and all-cause death (n = 914) was 5.9% (95% CI: 5.4%-6.4%), 10.7% (95% CI: 10.1%-11.4%), and 10.3% (95% CI: 9.7%-11.0%) in SELECT-eligible MI patients, respectively.”
Estimated postponement of 5% MACE incidence by 12 months with semaglutide
“Among these, treatment with semaglutide was estimated to postpone a 5% MACE incidence by 12 months.”
Substantial cardiovascular risk with 1 in 10 having a MACE event within 5 years
“In SELECT-eligible first-time MI patients with overweight or obesity and no diabetes, the cardiovascular risk was substantial with 1 in 10 having a MACE event within 5 years after first-time MI.”

Source: PubMed 42858539 · DOI 10.1016/j.jacadv.2026.103311 · all study summaries

Reported findings

Five-year incidence of MACE was 10.7% in SELECT-eligible MI patients

“Five-year incidence of second MI (n = 544), MACE (n = 975), and all-cause death (n = 914) was 5.9% (95% CI: 5.4%-6.4%), 10.7% (95% CI: 10.1%-11.4%), and 10.3% (95% CI: 9.7%-11.0%) in SELECT-eligible MI patients, respectively.”

Estimated postponement of 5% MACE incidence by 12 months with semaglutide

“Among these, treatment with semaglutide was estimated to postpone a 5% MACE incidence by 12 months.”

Substantial cardiovascular risk with 1 in 10 having a MACE event within 5 years

“In SELECT-eligible first-time MI patients with overweight or obesity and no diabetes, the cardiovascular risk was substantial with 1 in 10 having a MACE event within 5 years after first-time MI.”